Cochrane Evidence Synthesis and Methods ►

Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors versus single agent chemotherapy as second-line treatment for non–small-cell lung cancer wild-type or unknown status for EGFR

The aim of this systematic review is to evaluate the effectiveness and safety of EGFR-TKIs versus single-agent chemotherapy as second-line treatments in patients with advanced NSCLC and wild-type or unknown status for EGFR.

This is a protocol.

Published:

11 January 2018

Authors:

Créquit P, Yavchitz A, Trinquart L, Ravaud P, Cadranel J

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Créquit P, Yavchitz A, Trinquart L, Ravaud P, Cadranel J. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors versus single agent chemotherapy as second-line treatment for non–small-cell lung cancer wild-type or unknown status for EGFR. Cochrane Database of Systematic Reviews 2018, Issue 1. Art. No.: CD012901. DOI: 10.1002/14651858.CD012901